Original news and analysis on international IP policy
As officials gather this week to continue negotiations for a trade agreement among countries bordering the Pacific Ocean, a multi-country set of non-governmental organisations and academics urged a United Nations-appointed official to intervene, on grounds that the trade deal will severely impact the public health of poor populations in those countries.
Scientific advances in life sciences, in particular health, are being evaluated by experts this week in Lyon, France, with the stated hope of bringing new answers to global health challenges, such as funding, costs, and innovation.
The research-based pharmaceutical industry is working to bring a fresh face to the international public health policy arena in Geneva, most recently through a new initiative on technology transfer. Working through the industry’s Geneva-based trade association, the effort to be seen in a more positive light comes after years of doubts about the transparency of its involvement in these issues and could change the tenor of international negotiations.
Three United Nations agencies have joined together to explain to their member countries the little-understood but hard-won flexibilities to applying stiff international intellectual property rules. The focus of the new policy brief is on improving access to HIV treatment, and it offers a series of actions for governments and international organisations.
The newly created Medicines Patent Pool promises to increase access to HIV/AIDS medications in developing markets. Based in Geneva, Switzerland, the pool operates a scheme in which pharmaceutical patent holders voluntarily licence their drugs to generic manufacturers who then produce more affordable versions for patients in poorer countries
The Canadian Parliament is on the verge of amending the nation’s patent regime to make it easier for generic drug companies to provide low-cost HIV medications for developing countries.
After three days of intense negotiations on the role of the World Health Organization in the fight against low standard or falsified medicines, delegates provided recommendations for the UN agency. A subject of dissent was the relationship between the WHO and its taskforce against counterfeit medicines, with some countries calling for a suspension of the taskforce’s work, though in the end no consensus was found.
Myriad Genetics, a United States-based biotechnology company with exclusive patent rights over a key breast cancer diagnostic test in the US, may shift its patent strategy from its inventions to protecting its data in the face of drawn out litigation and upcoming competition, an industry journal has reported.
Patentable subject matter was discussed this week at the World Trade Organization with entrenched positions, according to sources, and the momentum started in October on ways to improve a public health exception within the WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement, appeared to have lost some steam.
The role of the World Health Organization in the safety, quality and efficacy of medical products is under scrutiny this week by member states and stakeholders. In particular, the focus is on the WHO’s role in the prevention and control of medical products of compromised quality, the organisation’s relationship with the international taskforce against counterfeit products, and the taskforce’s alleged focus on the protection of intellectual property rights rather than on public health issues. In several documents, the WHO tries to explain this fragile role.